Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rhCG Clear all
Terminated Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

NCT00042952
View directory record Official record
Conditions
Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage II Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Testicular Seminoma
Interventions
imatinib mesylate, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 7, 2026, 1:27 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

NCT02427529
View directory record Official record
Conditions
HCG
Interventions
Human Chorionic Gonadotropin, Placebo, Low calorie diet
Drug · Other
Lead sponsor
Dr. Emma's Corporation
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Colts Neck, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 7, 2026, 1:27 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

NCT05343572
View directory record Official record
Conditions
Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Interventions
Plerixafor
Drug
Lead sponsor
Hugh Taylor
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Orange, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 7, 2026, 1:27 PM EDT
Withdrawn Phase 2 Interventional

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364
View directory record Official record
Conditions
Stroke
Interventions
NTx™-265: rhCG, then rEPO, Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 7, 2026, 1:27 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

NCT03905603
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
ACTH, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
20 Years to 49 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 7, 2026, 1:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis

NCT04445025
View directory record Official record
Conditions
Infertility, Endometriosis
Interventions
Elagolix 200 MG, Leuprolide Acetate 3.75 MG/ML, Lab work
Drug · Diagnostic Test
Lead sponsor
Colorado Center for Reproductive Medicine
Other
Eligibility
21 Years to 42 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 7, 2026, 1:27 PM EDT
Terminated Phase 2 Interventional

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

NCT01094496
View directory record Official record
Conditions
Bladder Cancer
Interventions
CDX-1307 Vaccine Regimen, Chemotherapy
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 7, 2026, 1:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF

NCT01986374
View directory record Official record
Conditions
Infertility
Interventions
HCG is introduced
Drug
Lead sponsor
Servy Massey Fertility Insititute
Other
Eligibility
21 Years to 47 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 7, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Results available

MENOPUR® Versus FOLLISTIM®

NCT00802360
View directory record Official record
Conditions
Infertility
Interventions
Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Pasadena, California • San Diego, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Sep 7, 2026, 1:27 PM EDT
Not listed Not applicable Interventional

Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422759
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Spironolactone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 7, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

NCT00505752
View directory record Official record
Conditions
Infertility
Interventions
AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 36 Years · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 7, 2026, 1:27 PM EDT
Not listed Early Phase 1 Interventional

Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422746
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 7, 2026, 1:27 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 7, 2026, 1:27 PM EDT
Recruiting Phase 2 Interventional

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

NCT06440850
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Biospecimen Collection, Cobimetinib, Computed Tomography, Diagnostic Imaging, I-131 Uptake Test, Iodine I-131, Magnetic Resonance Imaging, Positron Emission Tomography, Recombinant Thyrotropin Alfa, Ultrasound Imaging, Vemurafenib
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 7, 2026, 1:27 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Detection of Urinary Human Chorionic Gonadotropin (hCG)

NCT05458778
View directory record Official record
Conditions
Pregnancy Detection
Interventions
Daily test with urine by the product
Device
Lead sponsor
Quanovate Tech Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Ramon, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 7, 2026, 1:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Investigational Oocyte Cryopreservation for Medical and Non Medical Indications

NCT04616417
View directory record Official record
Conditions
Infertility, Female, Deferred Childbearing
Interventions
Investigational Oocyte Cryopreservation
Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 7, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF

NCT01687712
View directory record Official record
Conditions
Infertility
Interventions
AFOLIA, Gonal-f® RFF
Drug
Lead sponsor
Fertility Biotech AG
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Tempe, Arizona • Encino, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 7, 2026, 1:27 PM EDT
Recruiting Phase 1 Interventional

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

NCT04886726
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
uhCG/EGF
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 7, 2026, 1:27 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709
View directory record Official record
Conditions
Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions
GnRH agonist, hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
21 Years to 33 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 7, 2026, 1:27 PM EDT
Terminated Not applicable Interventional

PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer

NCT06074055
View directory record Official record
Conditions
Infertility, Female
Interventions
FET Protocol
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 53 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Basking Ridge, New Jersey • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 7, 2026, 1:27 PM EDT
Terminated Phase 2 Interventional Results available

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00938314
View directory record Official record
Conditions
Stroke
Interventions
human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2011 · Synced Sep 7, 2026, 1:27 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Natural Versus Programmed Frozen Embryo Transfer (NatPro)

NCT04551807
View directory record Official record
Conditions
Pregnancy Related, Pre-Eclampsia
Interventions
Modified natural cycle, Programmed cycle
Procedure
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
788 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
15
States / cities
San Francisco, California • Sunnyvale, California • Orange, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 7, 2026, 1:27 PM EDT
Not listed No phase listed Observational

Proteomics & Glyco-Proteomic Analysis of Follicular Fluid

NCT01487486
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Normal Volunteers
Interventions
IVF Antagonist Protocol
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Sep 7, 2026, 1:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

NCT02145247
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
hCG
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 7, 2026, 1:27 PM EDT